In agreement with previously reported data showing that breast, colon, lung, and leukemia CSC are especially vulnerable to BCL-2 family inhibitors25, our findings highlight that inhibition of anti-apoptotic BCL-2 family members could represent a promising approach to target chemotherapy-resistant CSC and plasticity of glioblastoma and melanoma. This evidence concerns the gene BCL2 and melanoma.